These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 27585505)

  • 1. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.
    Grogan M; Scott CG; Kyle RA; Zeldenrust SR; Gertz MA; Lin G; Klarich KW; Miller WL; Maleszewski JJ; Dispenzieri A
    J Am Coll Cardiol; 2016 Sep; 68(10):1014-20. PubMed ID: 27585505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new staging system for cardiac transthyretin amyloidosis.
    Gillmore JD; Damy T; Fontana M; Hutchinson M; Lachmann HJ; Martinez-Naharro A; Quarta CC; Rezk T; Whelan CJ; Gonzalez-Lopez E; Lane T; Gilbertson JA; Rowczenio D; Petrie A; Hawkins PN
    Eur Heart J; 2018 Aug; 39(30):2799-2806. PubMed ID: 29048471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of clinical characteristics, distribution of red flags and prognosis in contemporary patients with wild-type transthyretin amyloidosis cardiomyopathy.
    Sanne Bøjet L; Bertil L; Anders Lehmann Dahl P; Jens Kæstel S; Tor Skibsted C; Steen Hvitfeldt P
    Ann Med; 2024 Dec; 56(1):2398735. PubMed ID: 39247984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.
    Cappelli F; Martone R; Gabriele M; Taborchi G; Morini S; Vignini E; Allinovi M; Di Gioia M; Bartolini S; Di Mario C; Perfetto F
    Can J Cardiol; 2020 Mar; 36(3):424-431. PubMed ID: 32145869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide.
    Klaassen SHC; Tromp J; Nienhuis HLA; van der Meer P; van den Berg MP; Blokzijl H; van Veldhuisen DJ; Hazenberg BPC
    Am J Cardiol; 2018 Jan; 121(1):107-112. PubMed ID: 29153245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.
    Connors LH; Sam F; Skinner M; Salinaro F; Sun F; Ruberg FL; Berk JL; Seldin DC
    Circulation; 2016 Jan; 133(3):282-90. PubMed ID: 26660282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of survival stratification in patients with wild-type cardiac amyloidosis.
    Siepen FAD; Bauer R; Voss A; Hein S; Aurich M; Riffel J; Mereles D; Röcken C; Buss SJ; Katus HA; Kristen AV
    Clin Res Cardiol; 2018 Feb; 107(2):158-169. PubMed ID: 28956153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma N-terminal pro-B-type natriuretic peptide as a predictor of perioperative and long-term outcome after vascular surgery.
    Schouten O; Hoeks SE; Goei D; Bax JJ; Verhagen HJ; Poldermans D
    J Vasc Surg; 2009 Feb; 49(2):435-41; discussion 441-2. PubMed ID: 19028043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Senile systemic amyloidosis: clinical features at presentation and outcome.
    Pinney JH; Whelan CJ; Petrie A; Dungu J; Banypersad SM; Sattianayagam P; Wechalekar A; Gibbs SD; Venner CP; Wassef N; McCarthy CA; Gilbertson JA; Rowczenio D; Hawkins PN; Gillmore JD; Lachmann HJ
    J Am Heart Assoc; 2013 Apr; 2(2):e000098. PubMed ID: 23608605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy.
    Kuyama N; Takashio S; Oguni T; Yamamoto M; Hirakawa K; Ishii M; Hanatani S; Oda S; Matsuzawa Y; Usuku H; Yamamoto E; Hirai T; Ueda M; Tsujita K
    J Am Heart Assoc; 2024 May; 13(10):e034518. PubMed ID: 38761073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.
    Manzano-Fernández S; Boronat-Garcia M; Albaladejo-Otón MD; Pastor P; Garrido IP; Pastor-Pérez FJ; Martínez-Hernández P; Valdés M; Pascual-Figal DA
    Am J Cardiol; 2009 Jun; 103(12):1753-9. PubMed ID: 19539088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis.
    Yunis A; Doros G; Luptak I; Connors LH; Sam F
    Am J Cardiol; 2019 Jul; 124(1):122-130. PubMed ID: 31053293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and
    Ochi Y; Kubo T; Nakashima Y; Baba Y; Hirota T; Yamasaki N; Yamashita T; Ueda M; Ando Y; Kitaoka H
    J Cardiol; 2020 Jan; 75(1):12-19. PubMed ID: 31324572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple staging system using biomarkers for wild-type transthyretin amyloid cardiomyopathy in Japan.
    Nakashima N; Takashio S; Morioka M; Nishi M; Yamada T; Hirakawa K; Ishii M; Tabata N; Yamanaga K; Fujisue K; Sueta D; Kanazawa H; Hoshiyama T; Hanatani S; Araki S; Usuku H; Yamamoto E; Ueda M; Matsushita K; Tsujita K
    ESC Heart Fail; 2022 Jun; 9(3):1731-1739. PubMed ID: 35191205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
    Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
    Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
    Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T;
    PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
    Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
    JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
    de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
    Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.